But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...